Research News
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis
-
Age-Related Macular Degeneration Research Advances
Research NewsRecent developments in research on age-related macular degeneration.
-
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
Research NewsThe company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
